Last reviewed 2026-05-14 · How we verify

Biotiren (dibromotyrosine)

Biotiren (generic name: dibromotyrosine) is a dibromotyrosine drug. It is currently in unknown development for Hyperthyroidism.

Biotiren works by inhibiting the production of thyroid hormones.

Biotiren (dibromotyrosine) is a small molecule drug in the dibromotyrosine class, originally developed by an unknown entity and currently owned by an unknown entity. It is used to treat hyperthyroidism, a condition characterized by an overproduction of thyroid hormones. The commercial status of Biotiren is unknown, and it is not clear if it is patented or available as a generic medication. Further information on its pharmacokinetics, safety, and efficacy is not available. As a result, its use should be approached with caution and under the guidance of a qualified healthcare professional.

At a glance

Mechanism of action

Think of it like a brake pedal for your thyroid gland. When you have hyperthyroidism, your thyroid gland is producing too many hormones, and Biotiren helps to slow down this process. This can help to bring your hormone levels back to a healthy balance.

Approved indications

• Hyperthyroidism

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Biotiren CI brief — competitive landscape report
• Biotiren updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Biotiren

Related

• Drug class: All dibromotyrosine drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Other
• Indication: Drugs for Hyperthyroidism

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing